A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a late-stage clinical-stage company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, we are developing antisense oligonucleotides (“ASOs”) to selectively restore protein levels. Our first investigational, new medicine in development, zorevunersen (STK-001), is a potential disease modifying medicine that is in late-stage clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is characterized by frequent, prolonged and refractory seizures beginning within the first year of life. The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with it. There are currently no disease modifying medicines approved for the treatment of Dravet syndrome.
| Segment | 2024 | % of Total |
|---|---|---|
Acadia Pharmaceuticals Inc. | $29M | 100% |
| Metric | TTM | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 206M | - | - | - |
| Net Income | 41M | -89M | -105M | -101M |
| EPS | $0.68 | $-1.65 | $-2.38 | $-2.60 |
| Free Cash Flow | 52M | -87M | -83M | -36M |
| ROIC | 9.6% | -38.9% | -65.6% | -54.7% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | 0.19 | 0.43 | 0.39 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | 27M | -101M | -115M | -104M |
| Operating Margin | 13.2% | - | - | - |
| ROE | 13.2% | -45.8% | -65.6% | -54.7% |
| Shares Outstanding | 57M | 54M | 44M | 39M |
| Metric | 2022 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | N/A | 206M |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | -104M | -115M | -101M | 27M |
| Op. Margin | N/A | N/A | N/A | 13.2% |
| Net Income | -101M | -105M | -89M | 41M |
| Net Margin | N/A | N/A | N/A | 19.7% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -54.7% | -65.6% | -38.9% | 9.6% |
| ROE | -54.7% | -65.6% | -45.8% | 13.2% |
| ROA | -39.5% | -45.9% | -35.6% | 11.3% |
| Cash Flow | ||||
| Op. Cash Flow | -32M | -81M | -87M | 53M |
| Free Cash Flow | -36M | -83M | -87M | 52M |
| Owner Earnings | -56M | -109M | -116M | 23M |
| CapEx | 4.0M | 1.6M | 203K | 480K |
| Maint. CapEx | 1.5M | 2.5M | 2.2M | 2.2M |
| Growth CapEx | 2.4M | 0 | 0 | 0 |
| D&A | 1.5M | 2.5M | 2.2M | 2.2M |
| CapEx/OCF | N/A | N/A | N/A | 0.9% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 23M | 25M | 27M | 27M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | N/A | N/A | N/A | -83M |
| Cash & Equiv. | N/A | N/A | N/A | 83M |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.39 | 0.43 | 0.19 | 0.00 |
| Interest Coverage | -33.4 | -11.6 | -8.0 | -8.0 |
| Equity | 185M | 160M | 229M | 308M |
| Total Assets | 256M | 228M | 272M | 360M |
| Total Liabilities | 71M | 69M | 43M | 30M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -297M | -402M | -491M | -491M |
| Working Capital | 213M | 185M | 193M | 193M |
| Current Assets | 244M | 215M | 233M | 233M |
| Current Liabilities | 31M | 31M | 40M | 40M |
| Per Share Data | ||||
| EPS | -2.60 | -2.38 | -1.65 | 0.68 |
| Owner EPS | -1.45 | -2.47 | -2.16 | 0.41 |
| Book Value | 4.76 | 3.63 | 4.25 | 5.39 |
| Cash Flow/Share | -0.82 | -1.84 | -1.61 | 0.75 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 38.9M | 44.0M | 53.9M | 57.1M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | 52.7 |
| P/FCF | N/A | N/A | N/A | 39.1 |
| EV/EBIT | N/A | N/A | N/A | 72.2 |
| Price/Book | 1.8 | 1.5 | 2.6 | 6.6 |
| Price/Sales | N/A | N/A | N/A | 10.0 |
| FCF Yield | -11.0% | -34.8% | -14.6% | 2.6% |
| Market Cap | 326M | 238M | 596M | 2.0B |
| Avg. Price | 15.55 | 7.63 | 11.54 | 35.86 |
| Year-End Price | 8.39 | 5.40 | 11.06 | 35.86 |
Stoke Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Stoke Therapeutics, Inc. trades at 52.7x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range.
Stoke Therapeutics, Inc. (STOK) has a current P/E ratio of 52.7, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
Stoke Therapeutics, Inc. (STOK) has a 5-year average return on invested capital (ROIC) of -53.0%. This is below average and may indicate limited pricing power.
Stoke Therapeutics, Inc. (STOK) has a market capitalization of $2.0B. It is classified as a mid-cap stock.
Stoke Therapeutics, Inc. (STOK) does not currently pay a regular dividend.
Based on historical P/E analysis, Stoke Therapeutics, Inc. (STOK) appears expensive. The current P/E of 52.7 is 252% above its historical median of 15.0.
Stoke Therapeutics, Inc. (STOK) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Stoke Therapeutics, Inc. (STOK) generated $-87 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Stoke Therapeutics, Inc. (STOK) has a debt-to-equity ratio of 0.19. This indicates a conservatively financed balance sheet.
Stoke Therapeutics, Inc. (STOK) reported earnings per share (EPS) of $-1.65 in its most recent fiscal year.
Stoke Therapeutics, Inc. (STOK) has a return on equity (ROE) of -45.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Stoke Therapeutics, Inc. (STOK), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Stoke Therapeutics, Inc. (STOK) has a book value per share of $4.25, based on its most recent annual SEC filing.